A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

NCT05327816 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

132

Enrollment

INDUSTRY

Sponsor class

Stopped Based on recent study data from VAC18193, it was decided to terminate the study. There are no underlying safety concerns to terminate VAC18195RSV1001

Conditions

Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention

Interventions

BIOLOGICAL: RSV preF-based Vaccine
DRUG: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.